Search

Tom N Grammatopoulos

from Boston, MA
Age ~53
Get Report
Also known as:
Thomas N Grammatopoulos, Tom M, Tom S, Tom L
Phone and address:
36 Symphony Rd, Boston, MA 02115
(617) 267-7867
Related to:
Gregory N Grammatopoulos, 59
Connected to:
Brittany Grammatica, 32Carla A Grammatica, 61Dan A Grammatis, 84Gaspare Grammatico, 72Lawrence J Grammatico, 67Louis G Grammatico, 72Panagiotis Grammatikopoulos, 33Salvatore J Grammatico, 70Daniel Gramme, 59Rose Gramme, 64

Tom Grammatopoulos Phones & Addresses

  • 36 Symphony Rd, Boston, MA 02115 (617) 267-7867
  • 36 Symphony Rd #2A, Boston, MA 02115 (617) 267-7867
  • 417 Massachusetts Ave, Roxbury, MA 02118 (617) 267-7867 (617) 437-9696
  • Racine, WI
  • 801 Dahlia St, Denver, CO 80220 (720) 941-3487
  • 801 Dahlia St #8, Denver, CO 80220 (720) 941-3487
  • 2015 Cynthia Dr, Champaign, IL 61821 (217) 351-7254
  • Berwyn, IL
  • Milwaukee, WI
  • Urbana, IL

Work

Company: Link medicine corporation - Cambridge, MA 2006 Position: Senior scientist ii

Education

School / High School: University of Illinois- Urbana, IL 2002 Specialities: Ph.D. in biology

Skills

Business Development • Cell Biology • Neuroscience • Drug Discovery • Assay Development • In Vivo Pharmacology • Mitochondria • Scientific Alliances • High Throughput Screening • Neurodegeneration • In Vitro Pharmacology • Translational Research • Strategy • Alliance Management • Project Management

Languages

Greek • English

Interests

Science and Technology • Education • Health

Industries

Biotechnology

Resumes

Resumes

Tom Grammatopoulos Photo 1

Senior Director Of Mitochondrial Biology

View page
Location:
Boston, MA
Industry:
Biotechnology
Work:
Lucy Therapeutics
Senior Director of Mitochondrial Biology
Charles River Laboratories 2015 - 2019
Senior Discovery Specialist and Business Development Director
Bioenergetics Llc 2011 - 2015
Chief Executive Officer and Managing Director
Boston University School of Medicine 2011 - 2013
Assistant Professor
Bioenergetics Llc 2011 - 2013
Founder, Member Board of Directors and Scientific Advisor
Education:
University of Illinois at Urbana - Champaign
Doctorates, Doctor of Philosophy, Biology Northeastern Illinois University
Masters, Biology University of Wisconsin - Milwaukee
Bachelors, Biology
Skills:
Business Development
Cell Biology
Neuroscience
Drug Discovery
Assay Development
In Vivo Pharmacology
Mitochondria
Scientific Alliances
High Throughput Screening
Neurodegeneration
In Vitro Pharmacology
Translational Research
Strategy
Alliance Management
Project Management
Interests:
Science and Technology
Education
Health
Languages:
Greek
English
Tom Grammatopoulos Photo 2

Tom Grammatopoulos

View page
Work:
Link Medicine Corporation
Cambridge, MA
2006 to 2011
Senior Scientist II
Lab of David Standaert
Charlestown, MA
2005 to 2006
Instructor
Harvard Medical School and Massachusetts General Hospital
Charlestown, MA
2004 to 2005
post-doctoral fellow
University of Colorado Health Sciences Center
Denver, CO
2002 to 2004
post-doctoral fellow
Lab of James Weyhenmeyer
Urbana, IL
1997 to 2002
Ph.D. Student
Lab of Jeff Leiden
Leiden
1996 to 1997
Senior Research Technologist
Lab of Earl Cheng
Chicago, IL
1994 to 1996
Research Assistant
University of Chicago
Chicago, IL
1993 to 1994
Research Assistant
University of Wisconsin
Milwaukee, WI
1991 to 1993
Laboratory Technician
Alliance Group Inc
Milwaukee, WI
1990 to 1991
Laboratory Technician
Education:
University of Illinois
Urbana, IL
2002
Ph.D. in biology
Northeastern Illinois University
Chicago, IL
1996
M.S. in Biology
University of Wisconsin
Milwaukee, WI
1993
B.S. in Biology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Tom N. Grammatopoulos
Mbr
BioEnergetics LLC
Research · Nonclassifiable Establishments · Noncommercial Research Organization
36 Symphony Rd SUITE 2A, Boston, MA 02115
36 Symphony Rd Apt2A, Boston, MA 02115

Publications

Us Patents

Treatment Of Lysosomal Storage Diseases

View page
US Patent:
20100184803, Jul 22, 2010
Filed:
Mar 7, 2008
Appl. No.:
12/529985
Inventors:
Tom Grammatopoulos - Boston MA, US
Craig J. Justman - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Valerie Christina Cullen - Squantum MA, US
International Classification:
A61K 31/47
A61K 31/4545
A61K 31/435
A61P 43/00
US Classification:
514312, 514326, 514299
Abstract:
Methods and compositions useful in the treatment or prevention of lysosomal storage diseases, such as Pompe's disease, Fabry's disease, Gaucher's disease, and Niemann-Pick disease, are provided. The treatment includes administering to a subject a farnesyl transferase inhibitor compound. The treatment may also include enzyme replacement therapy or gene therapy.

Treatment Of Mitochondrial Disorders Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20100331363, Dec 30, 2010
Filed:
Apr 30, 2010
Appl. No.:
12/771221
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 25/00
A61P 29/00
A61P 9/00
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to cause an improvement in mitochondrial health in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Mitochondrial Disorders Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20110060005, Mar 10, 2011
Filed:
Apr 7, 2010
Appl. No.:
12/756052
Inventors:
CRAIG J. JUSTMAN - CAMBRIDGE MA, US
TOM N. GRAMMATOPOULOS - BOSTON MA, US
BERKLEY A. LYNCH - CAMBRIDGE MA, US
ZHIHUA LIU - CHEVY CHASE MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 9/00
A61P 25/28
A61P 29/00
A61P 35/00
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an amount of a farnesyl transferase inhibitor, wherein the amount administered is sufficient to stimulate mitophagy in said subject. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20110294794, Dec 1, 2011
Filed:
Nov 13, 2009
Appl. No.:
13/129360
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4174
A61K 31/4439
A61K 31/5513
A61K 31/4545
A61P 25/28
A61P 25/14
A61P 27/02
A61P 29/00
A61P 9/00
A61P 35/00
A61P 25/16
A61K 31/496
A61P 3/00
US Classification:
514221, 514400, 51425405, 514343, 514290
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.

Treatment Of Proteinopathies Using A Farnesyl Transferase Inhibitor

View page
US Patent:
20100160372, Jun 24, 2010
Filed:
Nov 13, 2009
Appl. No.:
12/618265
Inventors:
Craig J. Justman - Cambridge MA, US
Tom N. Grammatopoulos - Boston MA, US
Berkley A. Lynch - Cambridge MA, US
Zhihua Liu - Chevy Chase MD, US
Assignee:
Link Medicine Corporation - Cambridge MA
International Classification:
A61K 31/4709
A61P 27/02
A61P 29/00
A61P 35/00
A61P 9/00
A61P 25/28
A61P 25/16
US Classification:
514312
Abstract:
Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA antagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant.
Control profile
Tom N Grammatopoulos from Boston, MA, age ~53 Get Report